Posted date:
ART-001 phase II study met its primary endpoint of response rate in patients with slow-flow vascular malformations
ART-001 phase II study met its primary endpoint of response rate in patients with slow-flow vascular malformations.
Kaken Pharmaceutical, ARTham’s parent company announced the details of positive results from the study in the following link:
https://ssl4.eir-parts.net/doc/4521/ir_material4/198438/00.pdf